发生反复急性排斥反应的移植受者的临床和免疫学特征。 - Suppr | 超能文献

Clinical and immunologic characteristics of transplant recipients with recurrent acute rejection episodes.

作者信息

Jacobs U, Niese D, Brensing K A, Klein B, Buszello H, Klehr H U

机构信息

Department of General Internal Medicine, University Hospital, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.

出版信息

Transplant Proc. 1996 Dec;28(6):3231-3.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Clinical and immunologic characteristics of transplant recipients with recurrent acute rejection episodes.发生反复急性排斥反应的移植受者的临床和免疫学特征。

Transplant Proc. 1996 Dec;28(6):3231-3.

2

How valid are risk factors for chronic transplant failure in renal transplant patients found in the literature with regard to our patients: results of a multivariate analysis.就我们的患者而言，文献中所发现的肾移植患者慢性移植失败的风险因素的有效性如何：多变量分析结果。

Transplant Proc. 1995 Feb;27(1):878-80.

3

Antidonor-HLA antibodies and soluble HLA antigens after kidney transplant.肾移植后的抗供体HLA抗体和可溶性HLA抗原

Transplant Proc. 1993 Dec;25(6):3279-80.

4

Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.心脏移植受者中免疫球蛋白M向免疫球蛋白G抗人白细胞抗原II类抗体的转换与细胞排斥反应和冠状动脉疾病风险增加相关。

Circulation. 2005 Oct 18;112(16):2468-76. doi: 10.1161/CIRCULATIONAHA.104.485003.

5

Clinical and immunological characteristics of transplant recipients with recurrent acute rejection episodes.复发性急性排斥反应发作的移植受者的临床和免疫学特征

Transplant Proc. 1997 Feb-Mar;29(1-2):181-3. doi: 10.1016/s0041-1345(96)00056-5.

6

HLA-DR matching and anti-donor-specific antibodies in kidney transplant recipients.肾移植受者的人类白细胞抗原-DR配型与抗供者特异性抗体

Transplant Proc. 1992 Dec;24(6):2514-6.

7

Kidney transplantation: generic HLA DR compatibility reduces acute rejection episodes.肾移植：通用型人类白细胞抗原DR相容性可减少急性排斥反应发作。

Transplant Proc. 1996 Oct;28(5):2812-3.

8

The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.HLA错配和免疫抑制治疗对小儿心脏移植受者早期排斥反应结局的影响。

J Heart Lung Transplant. 1998 Dec;17(12):1195-200.

9

Cellular immune activation reflects antiviral immunity and is a favorable prognostic marker in patients with cytomegalovirus infection.

Transplant Proc. 1993 Feb;25(1 Pt 2):1419-20.

10

Impact of HLA matching on the outcome of simultaneous pancreas-kidney transplantation.人类白细胞抗原配型对胰肾联合移植结局的影响。

Nephrol Dial Transplant. 2005 May;20 Suppl 2:ii48-53, ii62. doi: 10.1093/ndt/gfh1082.

引用本文的文献

1

A Drug Safety Briefing (II) in Transplantation from Real-World Individual Pharmacotherapy Management to Prevent Patient and Graft from Polypharmacy Risks at the Very Earliest Stage.药物安全简报（II）：从真实世界的个体化药物治疗管理到尽早预防患者和移植物多重用药风险的移植领域

Pharmaceuticals (Basel). 2024 Feb 25;17(3):294. doi: 10.3390/ph17030294.

2

A Drug Safety Concept (I) to Avoid Polypharmacy Risks in Transplantation by Individual Pharmacotherapy Management in Therapeutic Drug Monitoring of Immunosuppressants.一种药物安全理念（一）：通过免疫抑制剂治疗药物监测中的个体化药物治疗管理避免移植中的多重用药风险

Pharmaceutics. 2023 Sep 10;15(9):2300. doi: 10.3390/pharmaceutics15092300.